At six months post-infection, GDF-15 concentration remained significantly higher in the severe and moderate COVID-19 groups, compared to patients with mild COVID-19 and controls (p < 0·05, ANCOVA) (Fig. S2). The gene discussed is GDF15; the disease is COVID-19.